Comparative Pharmacology
Head-to-head clinical analysis: CISPLATIN versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CISPLATIN versus TREANDA.
CISPLATIN vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Platinum-based alkylating-like agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
50-100 mg/m² IV every 3-4 weeks; or 20 mg/m² IV daily for 5 days every 3-4 weeks.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateCisplatin + Digoxin
"Cisplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCisplatin + Digitoxin
"Cisplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCisplatin + Deslanoside
"Cisplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCisplatin + Acetyldigitoxin
"Cisplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is 20-30 hours (range 10-40 hours) in patients with normal renal function. This prolonged half-life is due to slow release of platinum from tissue binding and is clinically relevant for cumulative nephrotoxicity and ototoxicity.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal excretion accounts for 70-90% of cisplatin elimination, with approximately 20-50% excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent